Quarterly report pursuant to Section 13 or 15(d)

Description of Business and Basis of Presentation - Additional Information (Detail)

v3.24.1.1.u2
Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Basis Of Presentation [Line Items]      
Net loss $ (6,485) $ (5,849)  
Proceeds from the sale of common stock and pre-funded warrants, net of fees 2,784 8,503  
Working capital 3,600   $ 5,200
Cash and cash equivalents 6,393   6,566
Accounts receivable, net $ 5,687   $ 5,483
Common Stock, Par or Stated Value Per Share $ 0.001   $ 0.001
Principal Payment On Loan $ 165 0  
Proceeds from disposal of property, plant, and equipment 197 $ 0  
February 2024 Public Offering [Member]      
Basis Of Presentation [Line Items]      
Net loss (6,500)    
Proceeds from the sale of common stock and pre-funded warrants, net of fees 5,800    
Principal Payment On Loan 200    
Proceeds from disposal of property, plant, and equipment $ 200    
Biolase Stockholders [Member]      
Basis Of Presentation [Line Items]      
Common Stock, Par or Stated Value Per Share $ 0.001    
Reverse Stock Split a reverse stock split of BIOLASE common stock, par value $0.001 per share (the “common stock”), at a ratio between one-for-two (1:2) and one-for-one hundred (1:100). Immediately after the special meeting, BIOLASE's board of directors (the "Board") approved a one-for-one hundred (1:100) reverse stock split of the outstanding shares of the common stock (the “2023 Reverse Stock Split”).